On Tap: Novel Agents Awaiting US FDA Action In 2017
Executive Summary
New molecular entities and novel biologics on US FDA's user fee calendar for 2017.
An interactive chart of the more than 40 novel agents in line for FDA approval decisions in the upcoming year.
Click the column headers to sort the chart by parameters including sponsor, Prescription Drug User Fee Act (PDUFA) goal date, therapeutic area, and submission date. The search box can be used to filter the data. To see only approved products, for example, type "approved" in the box; to see only unapproved agents, type "pending" in the box.
This chart is adapted from the FDA Performance Tracker's User Fee Goal Dates chart, which is updated weekly and includes supplemental and non-NME original submissions as well as novel agents.